Table 4.
Significant fold-changes of differential miRNA expression for full array markers: employment duration adjusted for chronic fireground exposure (structure fire-hours or structure fire-runs) and time since most recent structure firea,b,c.
| miRNA | Employment duration |
Employment duration |
Select cancer associationc | Proposed role | Reference | ||||
|---|---|---|---|---|---|---|---|---|---|
| Adjusted for structure fire-hours and most recent structure fire |
Adjusted for structure fire-runs and most recent structure fire |
||||||||
| FC | 95% CI | FC | 95% CI | ||||||
| hsa-miR-494–3p | 0.60 | 0.54 | 0.66 | 0.65 | 0.59 | 0.72 | Prostate* | Oncogene | Cai and Peng [39] |
| hsa-miR-422a | 0.74 | 0.70 | 0.78 | 0.77 | 0.73 | 0.82 | CRC* | Tumor suppressor | Zheng et al. [34] |
| hsa-miR-26a-5p | 0.76 | 0.70 | 0.83 | 0.76 | 0.69 | 0.83 | HCC* | Tumor suppressor | Tan et al. [53] |
| hsa-miR-92a-3p | 0.78 | 0.73 | 0.83 | 0.79 | 0.73 | 0.84 | CRC | Tumor suppressor | Slattery et al. [40] |
| hsa-let-7f-5p | – | – | – | 0.80 | 0.73 | 0.87 | CRC* | Tumor suppressor | Ghanbari et al. [54] |
| hsa-miR-548a-3p | 1.30 | 1.16 | 1.46 | – | – | – | Prostate* | Oncogene | Nguyen et al. [55] |
| hsa-miR-556–3p | 1.32 | 1.17 | 1.48 | 1.34 | 1.18 | 1.53 | Osteosarcoma* | Oncogene | Xie et al. [41] |
| hsa-miR-548ad-3p | 1.38 | 1.21 | 1.58 | 1.39 | 1.20 | 1.60 | Breast | Oncogene | Sugita et al. [36] |
| hsa-miR-525–3p | 1.43 | 1.29 | 1.60 | 1.44 | 1.28 | 1.63 | HCC | Oncogene | Augello et al. [35] |
FC fold-change, CI confidence interval, CRC colorectal cancer, HCC hepatocellular carcinoma.
Effect for employment duration is an increase of 6 months. Models adjusted for employment duration, chronic fire exposure (fire-hours or fire-runs), time since most recent fire (see footnote a), age, BMI, ethnicity, Bonferroni correction, and batch effects.
An absolute FC >1.25 was applied to statistically significant miRNAs associated with length of service presented here.
Cancer association shown was selected based on the following criteria: (1) when possible reported association based on serum samples rather than tissue samples or cell assays, (2) reported association was validated in at least one other dataset, and (3) association reported in multiple types of samples (serum, tissue, cell lines, etc).
Select cancer associations based on circulating samples are indicated with an asterisk (*).